DelveInsight has launched a new report on BK virus Infection Pipeline
BK Virus (BKV) Infection also known as polyomavirus is a member of the human polyomavirus family. BKV resides dormant in uroepithelial cells as it is mostly acquired in childhood and is not known to cause tissue damage in immunocompetent individuals. The virus can become reactivated in case of immunodeficiency (e.g., secondary to HIV infection or immunosuppressive medications), and result in cellular damage and organ dysfunction.
Browse for free sample copy– https://www.delveinsight.com/sample-request/bk-virus-bkv-infection-pipeline-insight
BK virus Infection Pipeline analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of BK virus Infection Pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities
BK virus Infection Pipeline
The kidney, lung, eye, liver, and brain are sites of BK virus-associated disease, both primary and reactivated. BK virus infection in the kidney manifests as hemorrhagic cystitis, ureteric stenosis, nephritis and others. Pulmonary diseases that involve BK virus include pneumonitis and acute nonspecific upper respiratory tract infection.
In transplant recipients, however, BKV reactivation is common and can lead to distinctive pathological entities in different patient groups such as in renal transplant (RT) recipients, it is associated with nephropathy (BKVN) and ureteral stenosis, and in hematopoietic stem cell transplant (HSCT) recipients with hemorrhagic cystitis (HC).
BK virus Infection Symptoms
The symptoms of the infection include changes in vision and color of your urine (urine that is brown or red in color), pain while urinating, increase in urination frequency, cough, cold or trouble breathing, fever, muscle pain or weakness, seizures.
Unfortunately, there are no marketed drugs for this infection and the mainstay of managing reactivation is by immunosuppression, which is achieved by discontinuation of an agent, decreasing an agent, switching immunosuppressant within the same or another class, and steroid avoidance.
Emerging drugs included in the report
BK virus Infection Emerging Drugs
The dynamics of the BK Virus (BKV) Infection market is anticipated to change in the coming years owing to the improvement in the research and development. The launch of emerging therapies is expected during the forecast period of 2021–2030.
BK virus Infection Report Scope
Table of content
1. Report Introduction
2. BK virus (BKV) Infection
3. BK virus (BKV) Infection Current Treatment Patterns
4. BK virus (BKV) Infection – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. BK virus (BKV) Infection Late Stage Products (Phase-III)
7. BK virus (BKV) Infection Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. BK virus (BKV) Infection Discontinued Products
13. BK virus (BKV) Infection Product Profiles
14. BK virus (BKV) Infection Key Companies
15. BK virus (BKV) Infection Key Products
16. Dormant and Discontinued Products
17. BK virus (BKV) Infection Unmet Needs
18. BK virus (BKV) Infection Future Perspectives
19. BK virus (BKV) Infection Analyst Review
20. Appendix
21. Report Methodology
What are the report highlights?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/